Multiple sclerosis is a heterogennous disease with various neuropathological subtypes and variable genetic predisposition. These factors affect immune reactivity, reparation capacity of the central nervous system (CNS), clinical course of the disease, individual response to immunotherapy. Problem complexity of multiple sclerosis, diagnostics and proper therapy, often brings difficult questions. Introduction of new possibilities of immunomodulating therapy of MS: interferon beta and glatiramer acetate is significant in management of the disease. Immunomodulating therapy demonstrates that it is possible to alter natural course of relapse-remitting MS, reduce disease activity and put away progression of the disease. Recent knowledge of loss of axons from the beginning of the disease (1) has supported the initiation of the therapy by these agents immediately after the diagnosis is stated.